Menu
FDA DECISION ·
Etcamah + CDK4/6 inhibitor
camizestrant with abemaciclib, palbociclib or ribociclib · AstraZeneca
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with locally advanced or metastatic HR-positive, HER2-negative breast cancer when an FDA-authorized test detects an ESR1 mutation during aromatase inhibitor plus CDK4/6 inhibitor therapy.
SUPPORTING DATA
Evidence behind the decision
- Study
- SERENA-6 randomized 315 patients with ESR1 mutations detected on therapy to switch to camizestrant or continue the aromatase inhibitor, with CDK4/6 inhibition in both groups.
- Key result
- Median progression-free survival was 16.0 vs 9.2 months (hazard ratio 0.44, 95% CI, 0.31–0.60).
- Safety to report
- The label has a boxed warning for arrhythmia risk with concomitant QTc-prolonging drugs and includes a bradycardia warning.
- Evidence limits
- Overall survival was immature at the progression-free survival analysis. Continued approval may depend on confirmatory evidence.
LAMPGEN ANALYSIS
Why it matters
This makes an emerging ESR1 mutation actionable during ongoing treatment. SERENA-6 tested a switch before clinical progression, and overall survival was immature at the progression-free survival analysis.
What research teams should watch
Serial ctDNA collection, result turnaround and the clinical handoff determine whether a mutation-triggered switch can happen as intended. Medication reconciliation and cardiac safety checks also matter.
PRIMARY RECORDS